Ruxolitinib is increasingly being used in patients with graft-vs-host-disease (GVHD); a recent study found a link with transplant-associated thrombotic microangiopathy (TA-TMA) in patients with GVHD treated with the therapy.
For the first time, a study has shown that ruxolitinib is associated with transplant-associated thrombotic microangiopathy (TA-TMA) in patients with graft-vs-host-disease (GVHD) after receiving an allogeneic hematopoietic cell transplant.
Based on the association seen in their study, the researchers highlight the need for further studies to confirm this finding, as ruxolitinib is increasingly being used in patients with GVHD.
“A significant portion of ruxolitinib-treated patients with myelofibrosis or GVHD are expected to present with thrombocytopenia due to underlying diseases, as well as poikilocytosis in peripheral blood smear,” wrote the researchers. “In such patients, TMA might not be suspected by physicians, although its suspicion basically relies on the peripheral blood smear, an easily accessible tool for hematologists. Therefore, the finding of the present study is significant and useful for treating physicians.”
Among the 160 patients included in the study, 18 experienced TA-TMA. Analyses of these patients showed that TA-TMA was associated only with ruxolitinib treatment and severe GVHD. Patients receiving the JAK2 inhibitor were significantly more likely than patients not receiving the treatment to develop TA-TMA (37% vs 8%).
Notably, there was no correlation between ruxolitinib treatment and severe GVHD.
In patients with TA-TMA, management included steroids, cyclosporine inhibitor cessation, plasma infusions, and plasma exchange. Management strategies also included complement inhibition with eculizumab, which was associated with a significantly higher Endothelial Activation and Stress Index (EASIX) and soluble C5b-9 levels.
“In terms of TA-TMA management, our study is in line with previous reports in adult TA-TMA suggesting that OS remains low (approximately 30%) despite effectiveness of eculizumab,” explained the researchers. “Several issues remain to be further investigated: timing of initiation, proper patient selection, dosing, and duration of therapy in transplanted patients. In terms of timing of initiation and patient selection, our study confirms previous findings suggesting that EASIX might be used as a prognostic marker in patients with endothelial dysfunction syndrome.”
Surviving patients were followed for a median of 38.4 months, with a 5-year overall survival of 52.9%, which was unfavorably predicted by TA-TMA, severe acute GVHD, and lower number of infused CD34+ cells.
Reference
Gavriilaki E, Sakellari I, Chatzikonstantinou T, et al. Predictors of transplant-associated thrombotic microangiopathy in patients with overlap or chronic graft-vs-host-disease. Transplant Proc. Published online August 18, 2021. doi:10.1016/j.transproceed.2021.07.043
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen